Department of Radiation Oncology, British Columbia Cancer Agency, Kelowna, British Columbia, Canada.
Urology. 2012 Sep;80(3):649-55. doi: 10.1016/j.urology.2012.03.051. Epub 2012 Jun 13.
To examine a 2-year cohort of patients treated with brachytherapy to determine the likelihood of unfavorable pathologic features using a nomogram recently developed at our center to estimate the likelihood of Gleason score upgrading for patients with favorable prostate cancer undergoing radical prostatectomy. The brachytherapy outcomes for patients with a high likelihood of upgrading were compared with those with a lower likelihood to affirm the effectiveness of brachytherapy in this setting. Information on the likelihood of upgrading could help in the selection between active treatment and surveillance for patients with favorable-risk prostate cancer.
The records were examined for 259 men undergoing prostate brachytherapy in 2006 to 2007, of whom 217 had favorable risk cancer. The likelihood of Gleason score upgrading (GSU) was predicted using the radical prostatectomy-derived nomogram.
The median age was 62 years (range 44-77), and the median prostate-specific antigen level was 4.71 ng/mL (range 0.56-9.87). Central pathology review was available for 88%, and 83% had undergone extended biopsies. Two men had received androgen deprivation therapy for prostate downsizing. The median predicted likelihood of GSU was 51.2%. The median prostate-specific antigen level for 199 patients without treatment failure after a median follow-up of 4.2 years in this cohort was 0.07 ng/mL (interquartile range undetectable to 0.23).
In the present cohort of patients with favorable-risk prostate cancer treated with brachytherapy, the estimated likelihood of GSU using the surgically derived nomogram was substantial. Follow-up with prostate-specific antigen measurement has indicated that brachytherapy is a highly effective treatment option despite less favorable clinical and pathologic factors. Patients should not be discouraged from brachytherapy on the basis of a high likelihood of GSU.
通过分析本中心最近开发的一种预测前列腺根治性切除术患者 Gleason 评分升级概率的列线图,对接受近距离放射治疗的 2 年队列患者进行研究,以确定使用该图预测的不良病理特征的可能性。比较高危升级患者与低危升级患者的近距离放射治疗结果,以证实该治疗方案在这种情况下的有效性。这种升级概率的信息有助于在选择对低危前列腺癌患者进行积极治疗或监测时提供参考。
对 2006 年至 2007 年间接受前列腺近距离放射治疗的 259 名男性患者的记录进行了检查,其中 217 例为低危癌症患者。使用源于前列腺根治性切除术的列线图预测 Gleason 评分升级(GSU)的可能性。
中位年龄为 62 岁(范围为 44-77 岁),中位前列腺特异性抗原水平为 4.71ng/ml(范围为 0.56-9.87ng/ml)。88%的患者接受了中心病理复查,83%的患者接受了扩展活检。有 2 名患者接受了雄激素剥夺治疗以缩小前列腺体积。中位预测 GSU 概率为 51.2%。在该队列中,中位随访时间为 4.2 年,199 例未发生治疗失败的患者的中位前列腺特异性抗原水平为 0.07ng/ml(四分位距为不可检测至 0.23ng/ml)。
在本队列接受近距离放射治疗的低危前列腺癌患者中,使用手术衍生列线图预测的 GSU 概率相当大。基于前列腺特异性抗原水平的随访结果表明,尽管存在更不利的临床和病理因素,近距离放射治疗仍是一种非常有效的治疗选择。不应因 GSU 概率高而劝阻患者接受近距离放射治疗。